| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2019 | CUMBERLAND PHARMACEUTICALS, INC. | 1600 W END AVE STE 1300 | NASHVILLE | TN | 37203-7003 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 000 | 1 | FDA | 11/26/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = -$15,355 ) |
| | 2023 | 2019 | CUMBERLAND PHARMACEUTICALS, INC. | SUITE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 000 | 1 | FDA | 8/30/2023 | $0 |
| | 2023 | 2019 | CUMBERLAND PHARMACEUTICALS, INC. | SUITE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 000 | 1 | FDA | 8/30/2023 | $0 |
| | 2023 | 2019 | CUMBERLAND PHARMACEUTICALS, INC. | SUITE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 000 | 1 | FDA | 8/30/2023 | $0 |
| | 2023 | 2019 | CUMBERLAND PHARMACEUTICALS, INC. | 1600 W END AVE STE 1300 | NASHVILLE | TN | 37203-7003 | DAVIDSON | USA | R44CA228756 | Targeting DNA damage response pathways for the treatment of advanced lung cancer | 000 | 3 | NIH | 2/9/2023 | -$15,355 |
|
| Issue Date FY: 2022 ( Subtotal = -$5,247 ) |
| | 2022 | 2019 | CUMBERLAND PHARMACEUTICALS, INC. | SUITE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R44CA228756 | Targeting DNA damage response pathways for the treatment of advanced lung cancer | 000 | 3 | NIH | 4/28/2022 | -$5,247 |
| | 2022 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 000 | 1 | FDA | 8/5/2022 | $0 |
| | 2022 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 000 | 1 | FDA | 8/5/2022 | $0 |
| | 2022 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 000 | 1 | FDA | 8/5/2022 | $0 |
| | 2022 | 2016 | CUMBERLAND PHARMACEUTICALS, INC. | SUITE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R41DK106779 | A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes | 000 | 1 | NIH | 10/1/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R44CA228756 | Targeting DNA damage response pathways for the treatment of advanced lung cancer | 000 | 3 | NIH | 7/28/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $97,112 ) |
| | 2020 | 2020 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 001 | 1 | FDA | 9/16/2020 | $97,112 |
| | 2020 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 000 | 1 | FDA | 11/8/2019 | $0 |
| | 2020 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 000 | 1 | FDA | 11/8/2019 | $0 |
| | 2020 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 000 | 1 | FDA | 11/8/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $2,139,876 ) |
| | 2019 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 000 | 1 | FDA | 9/12/2019 | $300,000 |
| | 2019 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R44CA228756 | Targeting DNA damage response pathways for the treatment of advanced lung cancer | 001 | 3 | NIH | 8/16/2019 | $1,070,134 |
| | 2019 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 001 | 1 | FDA | 9/18/2019 | -$155,000 |
| | 2019 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 002 | 1 | FDA | 9/28/2019 | $0 |
| | 2019 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 002 | 1 | FDA | 9/28/2019 | $0 |
| | 2019 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 002 | 1 | FDA | 9/28/2019 | $769,742 |
| | 2019 | 2019 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R01FD006371 | A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018) | 001 | 1 | FDA | 9/18/2019 | $155,000 |
| | 2019 | 2018 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R44CA228756 | Targeting DNA damage response pathways for the treatment of advanced lung cancer | 000 | 2 | NIH | 10/23/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $924,071 ) |
| | 2018 | 2018 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R44CA228756 | Targeting DNA damage response pathways for the treatment of advanced lung cancer | 000 | 2 | NIH | 9/11/2018 | $924,071 |
| | 2018 | 2016 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R41DK106779 | A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes | 000 | 1 | NIH | 9/13/2018 | $0 |
| | 2018 | 2014 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R41ES025596 | Targeting DNA damage response pathways for the treatment of advanced lung cancer | 000 | 1 | NIH | 9/17/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2014 | CUMBERLAND PHARMACEUTICALS INC. | 2525 WEST END AVE STE 950 | NASHVILLE | TN | 37203-1608 | DAVIDSON | USA | R41ES025596 | Targeting DNA damage response pathways for the treatment of advanced lung cancer | 000 | 1 | NIH | 1/4/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $224,999 ) |
| | 2016 | 2016 | CUMBERLAND PHARMACEUTICALS INC | 2525 WEST END AVENUE | NASHVILLE | TN | 37203 | DAVIDSON | USA | R41DK106779 | A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes | 000 | 1 | NIH | 8/24/2016 | $224,999 |
|
| Issue Date FY: 2014 ( Subtotal = $224,910 ) |
| | 2014 | 2014 | CUMBERLAND PHARMACEUTICALS INC | 2525 WEST END AVENUE | NASHVILLE | TN | 37203 | DAVIDSON | USA | R41ES025596 | Targeting DNA damage response pathways for the treatment of advanced lung cancer | 000 | 1 | NIH | 9/22/2014 | $224,910 |
|
| Issue Date FY: 2012 ( Subtotal = $246,084 ) |
| | 2012 | 2012 | CUMBERLAND PHARMACEUTICALS INC | 2525 WEST END AVENUE | NASHVILLE | TN | 37203 | DAVIDSON | USA | R41AG043342 | PRECLINICAL DEVELOPMENT OF A NEW DRUG FOR TREATING ANEMIA OF CHRONIC INFLAMMATION | 000 | 1 | NIH | 4/16/2012 | $246,084 |
|
| Issue Date FY: 2010 ( Subtotal = $0 ) |
| | 2010 | 2009 | CUMBERLAND PHARMACEUTICALS INC | 2525 WEST END AVENUE | NASHVILLE | TN | 37203 | DAVIDSON | USA | R41HL090108 | MANNAN, A POTENTIAL THERAPEUTIC FOR ASTHMA | 000 | 1 | NIH | 1/13/2010 | $0 |
| | 2010 | 2009 | CUMBERLAND PHARMACEUTICALS INC | 2525 WEST END AVENUE | NASHVILLE | TN | 37203 | DAVIDSON | USA | R41CA130191 | RADIOPROTECTION BY USE OF TOPICAL LITHIUM FORMULATIONS | 000 | 1 | NIH | 10/21/2009 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $233,333 ) |
| | 2009 | 2009 | CUMBERLAND PHARMACEUTICALS INC | 2525 WEST END AVENUE | NASHVILLE | TN | 37203 | DAVIDSON | USA | R41CA130191 | RADIOPROTECTION BY USE OF TOPICAL LITHIUM FORMULATIONS | 000 | 1 | NIH | 9/21/2009 | $121,528 |
| | 2009 | 2009 | CUMBERLAND PHARMACEUTICALS INC | 2525 WEST END AVENUE | NASHVILLE | TN | 37203 | DAVIDSON | USA | R41HL090108 | MANNAN, A POTENTIAL THERAPEUTIC FOR ASTHMA | 000 | 1 | NIH | 1/23/2009 | $111,805 |
| | 2009 | 2009 | CUMBERLAND PHARMACEUTICALS INC | 2525 WEST END AVENUE | NASHVILLE | TN | 37203 | DAVIDSON | USA | R41CA130191 | RADIOPROTECTION BY USE OF TOPICAL LITHIUM FORMULATIONS | 001 | 1 | NIH | 10/21/2009 | $0 |
| | 2009 | 2005 | CUMBERLAND PHARMACEUTICALS INC | 2525 WEST END AVENUE | NASHVILLE | TN | 37203 | DAVIDSON | USA | R42HL064530 | TGF-BETA FOR PLEURODESIS | 000 | 3 | NIH | 1/7/2009 | $0 |
|
| Issue Date FY: 2005 ( Subtotal = $367,451 ) (Continued on the next page) |
|
